If we recall that approximately 25% of total weight loss in persons with obesity is accounted for by FFM, the authors found that fat free mass accounted for 33%, 39%, and 25% of total weight loss for retatrutide ( Phase 2 data only, not yet FDA approved), semaglutide and tirzepatide respectively whereas fat mass loss accounted for 67%, 61%, and 75% respectively
Likewise, minority and low-income youths have been underrepresented in trials, so we lack evidence on GLP-1 RA effects across diverse racial/ethnic groups
At Health First, weight management is treated as an ongoing health journey one supported by evidence-based care, local providers, and personalized support aimed at improving quality of life, one person at a time
Feel Better, Faster with Mobile IV Drip Therapy Such a good experience